RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Schmitt, Friedhelm C
Kliegis, Leon M
MetadataShow full item record
AbstractHepatic encephalopathy (HE) is a clinically significant complication of liver cirrhosis impacting on the patients' quality of life. Minimal hepatic encephalopathy (MHE) is diagnosed by psychometric tests, found in up to 80 % of patients with liver cirrhosis and carries a high risk of progression to overt HE. Continuous therapy with rifaximin in combination with lactulose significantly reduces the risk of overt HE, recurrence of HE and HE-related hospitalizations in randomized, double-blind, placebo-controlled clinical trials. Rifaximin is approved for the therapy of overt HE in Germany. Treatment with lactulose has been shown to improve cognitive functions in patients with liver cirrhosis. Data from prospective clinical trials comparing the efficacy of rifaximin alone against a combination of rifaximin and lactulose in the treatment of MHE are scarce. Changes in the microbiome of the upper and lower gastrointestinal tract as a result of therapy with rifaximin have not yet been addressed in clinical studies.
CitationRiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial. 2016, 17 (1):111 Trials
AffiliationHelmholtz Centre for infection research, Inhoffenstr. 7, 38124 Braunschweig, Germany.
The following license files are associated with this item:
- Long-Term Effect of Rifaximin with and without Lactulose on the Active Bacterial Assemblages in the Proximal Small Bowel and Faeces in Patients with Minimal Hepatic Encephalopathy.
- Authors: Schulz C, Schütte K, Vilchez-Vargas R, Vasapolli R, Malfertheiner P
- Issue date: 2019
- Rifaximin vs. lactulose in treatment of minimal hepatic encephalopathy.
- Authors: Sidhu SS, Goyal O, Parker RA, Kishore H, Sood A
- Issue date: 2016 Mar
- Minimal hepatic encephalopathy in cirrhosis- how long to treat?
- Authors: Goyal O, Sidhu SS, Kishore H
- Issue date: 2017 Jan-Feb 2017
- Evolving concepts: the negative effect of minimal hepatic encephalopathy and role for prophylaxis in patients with cirrhosis.
- Authors: Prakash RK, Kanna S, Mullen KD
- Issue date: 2013 Sep
- Durability of rifaximin response in hepatic encephalopathy.
- Authors: Neff GW, Jones M, Broda T, Jonas M, Ravi R, Novick D, Kaiser TE, Kemmer N
- Issue date: 2012 Feb